To screen ETFs by asset class, performance, yield and more, check out the
This user currently has no profile.
Possessing just over a quarter century working in the financial industry, my career commenced at Merrill, where I worked as a sales assistant. Soon after, I became a broker, moving into corporate finance/syndication for micro- and small-caps with a regional firm. My journalistic and speech communications education and experiential background has proven key in helping numerous client and non-client companies, both privately and publicly held.
I've worked as a private consultant since the early '90s. Areas of primary interest are bio-pharma, pharma, bio-tech, some nutraceutical and technology. Finally, my intent, for any deserving company, whether client or not, and especially those labeled "emerging
growth/micro-cap" is to communicate their existence, and subsequently, news as related to their core operational developments. These efforts are of particular importance if the company about which I write offers promise for anything that may genuinely aid the world's population, regardless of socioeconomic status.
Stocks - long
Currently, there is no company profile for WRDC6B.
Currently, there are no blog details for WRDC6B.
Currently, there are no book details for WRDC6B.
Noble Financial Raises its
Target Price From $4.00 to $8.00 on Company's Recent Progress
Jan 19, 2011
Thank you for writing such ...
Why Big Pharma Is the New Big Biotech
IBIO, Fiocruz/Bio-Manguinhos Deal Jumpstarts New Vaccine Development
IBIO: Developing a Long Uptrend and Broader Investor Interest?
iBio Picked Up by Goldman Small Cap Research, Jan. 5
iBio, Promising for World Wide Health
Xignite quote data
© 2014 Seeking Alpha